Kris on Oncology

• Confronting Isolation Among Cancer Patients During COVID-19   Dr Mark Kris discusses the importance of oncologists helping their patients to overcome physical and psychological isolation during these unprecedented times.
  Medscape Oncology, August 28, 2020
• Gefitinib Plus Chemo for NSCLC With EGFR Mutations   Dr Mark Kris discusses recent studies that provide evidence for a new standard of care -- gefitinib plus chemotherapy -- in patients with NSCLC and an EGFR-activating mutation.
  Medscape Oncology, July 27, 2020
• When to Add Chemo to IO in Lung Cancer? New Data From ASCO 2020   Immunotherapeutic agents are bringing our lung cancer patients closer to cure, says Mark Kris.
  Medscape Oncology, July 22, 2020
• ADAURA Trial Changes Lung Cancer Treatment in Two Important Ways   Dr Mark Kris discusses recent practice-changing abstracts in lung cancer, presented at the virtual 2020 ASCO meeting.
  Medscape Oncology, July 13, 2020
• Progress in Targeted Therapy for Lung Cancer: New Data   Dr Mark Kris explains why he is even more hopeful when it comes to targeted therapy for lung cancer after seeing several trial results presented during this year's virtual ASCO meeting.
  Medscape Oncology, June 30, 2020
• Should ADAURA Trial Results Change Practice in NSCLC?   Dr Mark Kris says yes and explains why he thinks 3-year treatment with osimertinib should become the new standard of care for patients with EGFR mutation–positive NSCLC.
  Medscape Oncology, June 30, 2020
• Caring for Cancer Patients in This New Normal   As the pandemic continues, Dr Mark Kris says that 'maintaining care is essential' for our cancer patients and offers suggestions on how to do so.
  Medscape Oncology, June 23, 2020
• Don't Let COVID-19 'Distract' You From Your Cancer Care Efforts   While COVID-19 cannot be ignored, Dr Mark Kris says it can be managed like anything else, and offers suggestions for the care of advanced cancer patients during this time.
  Medscape Oncology, June 09, 2020
• Stay the Course With Cancer Care Even During COVID-19   Treating patients with cancer during COVID-19 is not 'business as usual,' says Dr Mark Kris, who advises a methodical approach in deciding when and how to conduct patient visits and treatment.
  Medscape Oncology, June 02, 2020
• Practical Tips on Cancer Care During the COVID-19 Pandemic   Dr Mark Kris provides tips for managing patients with cancer during the COVID-19 pandemic.
  Medscape Oncology, April 24, 2020
• What We Owe Patients While They Await a Cancer Diagnosis   Dr Mark Kris offers advice on how we can help to alleviate the anxiety being experienced by our patients as they await their cancer diagnosis.
  Medscape Oncology, April 23, 2020
• In Cancer Medicine, Precision Is Worth the Wait   Dr Mark Kris stresses the importance of having patients understand the time involved in a cancer diagnosis being made and why it matters.
  Medscape Oncology, April 20, 2020
• Oncologists, Pathologists Need a 'Culture Change' on Biopsies   Dr Mark Kris discusses the profound effect that the wait time between cancer being diagnosed and treatment being initiated has on both patients and physicians.
  Medscape Oncology, April 03, 2020
• Cancer Patients Are Concerned About Cancer, Then COVID-19   Dr Mark Kris discusses how patients with cancer are primarily concerned about their cancer and its consequences, followed by concerns about COVID-19.
  Medscape Oncology, April 03, 2020
• Let's Not Minimize the Impact of Progression-Free Survival   The excitement of KEYNOTE-001, presented at this year's ASCO, was imperceptible in the published article. Dr Mark Kris says we shouldn't miss the real message: Patients were disease free at 5 years.
  Medscape Oncology, November 08, 2019
• FLAURA Data Miss the Point: PFS Matters   Dr Mark Kris shares his disappointment that the recent FLAURA results did not evaluate progression-free survival, a parameter that means so much to patients.
  Medscape Oncology, October 31, 2019
• New Data Challenge Current Standard in Treating EGFR+ Lung Cancer   Dr Mark Kris discusses three new and 'disruptive' studies presented at ASCO showing that we 'need to do more' with EGFR-mutant NSCLC.
  Medscape Oncology, September 10, 2019
• Next Advances in Lung Cancer Target MET, KRAS   Although this past ASCO meeting may have lacked drama and excitement, Mark Kris was encouraged by studies on new targets and new drug constructs in lung cancer.
  Medscape Oncology, August 14, 2019
• 'A Really Big Year' for Lung Cancer Treatment   Dr Mark Kris reviews promising new research in neoadjuvant and adjuvant therapies for lung cancer, presented at ASCO 2019.
  Medscape Oncology, July 30, 2019
• Exceeding Our Patients' Expectations Needs to Be the Goal Now   Merely meeting expectations is not good enough anymore, says Dr Mark Kris. We are poised to cure some cancers and give our patients' lives back to them. We should not hesitate to do it.
  Medscape Oncology, July 23, 2019